Skip to main content

Table 1 Baseline and 6-month characteristics of treatment groups (Me [IQR])

From: Influence of adjunctive azithromycin on microbiological and clinical outcomes in periodontitis patients: 6-month results of randomized controlled clinical trial

 

Baseline characteristics

6-month characteristics

Control group

Test group

p

Control group

Test group

p

Teeth with DS (n)

18.0 (16.3–21.3)

14.0 (12.3–22.3)

0.412

4.0a (1.0–10.0)

4.0a (0.0–7.0)

0.616

DS (n)

47.0 (28.0–63.8)

34.0 (23.3–62.3)

0.397

5.0a (1.0–22.3)

4.0a (0.0–11.0)

0.497

DS on molars (n)

15.0 (10.3–23.0)

18.0 (11.3–23.5)

0.661

1.0a (0.3–6.8)

2.0a (0.0–6.5)

0.801

PlI (%)

40.0 (20.0–50.0)

30.0 (20.0–50.0)

0.726

10.0a (2.0–20.0)

10.0a (4.0–10.0)

0.988

PD (mm)

4.1 (3.6–4.5)

3.9 (3.7–4.5)

0.838

2.9a (2.4–3.6)

2.7a (2.4–3.1)

0.484

REC (mm)

0.4 (0.3–0.6)

0.4 (0.2–0.7)

0.895

0.7a (0.5–1.1)

0.6a (0.5–1.0)

0.661

CAL (mm)

4.2 (3.6–4.9)

4.2 (3.7–4.8)

0.988

3.3a (2.6–4.3)

3.3a (2.7–3.7)

0.770

BOP (%)

80.0 (60.0–90.0)

70.0 (50.0–90.0)

0.620

20.0a (10.0–40.0)

20.0a (10.0–20.0)

0.651

  1. Me median value, IQR interquartile range, DS diseased sites (PD ≥ 5 mm + BOP); PlI plaque index; PD probing depth; REC recession; CAL clinical attachment loss; BOP bleeding on probing; a, statistically significant change in comparison to baseline